Brooksbank Jeremy A, Faulkenberg Kathleen D, Tang W H Wilson, Martyn Trejeeve
Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart and Vascular Institute, Cleveland Clinic, Euclid Ave, Cleveland, OH USA.
Department of Pharmacy, University of Kentucky Healthcare, Lexington, KY USA.
Curr Treat Options Cardiovasc Med. 2023;25(5):93-110. doi: 10.1007/s11936-023-00979-4. Epub 2023 Apr 5.
To examine the emerging data for novel strategies being studied to improve use and dose titration of guideline-directed medical therapy (GDMT) for patients with heart failure (HF).
There is mounting evidence to employ novel multi-pronged strategies to address HF implementation gaps.
Despite high-level randomized evidence and clear national society recommendations, a large gap persists in use and dose titration of guideline-directed medical therapy (GDMT) in patients with heart failure (HF). Accelerating the safe implementation of GDMT has proven to reduce the morbidity and mortality associated with HF but remains an ongoing challenge for patients, clinicians, and health systems. In this review, we examine the emerging data for novel strategies to improve the use of GDMT including the use of multidisciplinary team-based approaches, nontraditional patient encounters, patient messaging/engagement, remote patient monitoring, and electronic health record (EHR)-based clinical alerts. While societal guidelines and implementation studies have focused on heart failure with reduced ejection fraction (HFrEF), expanding indications and evidence for the use of sodium glucose cotransporter2 (SGLT2i) will necessitate implementation efforts across the LVEF spectrum.
探讨正在研究的新型策略的最新数据,这些策略旨在改善心力衰竭(HF)患者的指南指导药物治疗(GDMT)的使用和剂量滴定。
越来越多的证据表明,应采用新型多管齐下的策略来解决心力衰竭实施方面的差距。
尽管有高级别的随机证据和明确的国家学会建议,但心力衰竭(HF)患者在指南指导药物治疗(GDMT)的使用和剂量滴定方面仍存在很大差距。事实证明,加速GDMT的安全实施可降低与HF相关的发病率和死亡率,但对患者、临床医生和卫生系统来说,这仍然是一项持续的挑战。在本综述中,我们探讨了改善GDMT使用的新型策略的最新数据,包括使用多学科团队方法、非传统患者诊疗、患者信息传递/参与、远程患者监测以及基于电子健康记录(EHR)的临床警报。虽然社会指南和实施研究主要关注射血分数降低的心力衰竭(HFrEF),但随着钠-葡萄糖协同转运蛋白2(SGLT2i)使用的适应症扩大和证据增加,有必要在整个左心室射血分数(LVEF)范围内开展实施工作。